Federal Medicaid work requirements mandating 80 hours monthly of community engagement for expansion adults aged 19-64 take effect January 2027, with states responsible for defining exemptions, compliance pathways, and verification processes. The rule creates significant operational and financial uncertainty for Medicaid managed care plans, which must prepare enrollment systems and work with state agencies on implementation decisions that will vary substantially by jurisdiction. Stakeholders including MCOs should engage now during the comment period and state planning phase to shape exemption policies, hardship provisions, and compliance demonstration approaches that will directly affect coverage continuity and plan operations.

CMS's June 2026 interim final rule establishes Medicaid community engagement requirements effective January 2027, applying to non-pregnant adults 19-64 in expansion populations across 43 states and DC. The rule includes a stricter-than-expected medical frailty exemption requiring ADL impairment and prohibits states from delegating eligibility verification to MCOs, while CMS projects combined 15% disenrollment from noncompliance and procedural issues. MCOs must now prepare operational strategies to mitigate enrollment loss and support members in meeting requirements, even as they cannot directly perform eligibility verification.

Federal disruption to ACIP has created challenges for Medicaid managed care organizations as they manage immunization coverage policies amid fragmented guidance from multiple clinical bodies. While a March 2026 injunction preserved broad vaccine coverage requirements, the uncertainty has forced states and health plans to independently maintain coverage policies, creating implementation complexity. The article explores how public health stakeholders are adapting to fill federal policy gaps through alternative recommendation pathways and trust-building efforts.

CMS is overhauling kidney care through transplant system modernization, new organ procurement standards, and the mandatory IOTA Model launched in mid-2025, while simultaneously sunsetting underperforming value-based care models like ESRD Treatment Choices. The piece examines how federal payment reforms, emerging xenotransplant technology, and refined Kidney Care Choices models are reshaping the dialysis and transplant ecosystem. While primarily Medicare-focused, these structural changes affect Medicaid managed care plans covering dual-eligible populations and states with integrated care models for members with end-stage renal disease.

The 2026 CMS Quality Conference outlined major policy directions affecting both Medicare and Medicaid managed care, emphasizing prevention-focused models, technology-enabled whole-person care, real-time quality measurement, and AI integration. CMS leadership signaled that quality strategies will increasingly prioritize upstream preventive interventions and align payment incentives with clinical outcomes, requiring health plans to demonstrate how their programs contribute to prevention and reduce downstream utilization. These emerging federal priorities will shape how Medicaid MCOs structure their quality improvement programs, demonstrate value, and respond to evolving state contract requirements.

Medicaid programs are increasingly moving away from bundled payment methodologies for cell and gene therapies in order to separately identify these drugs and collect manufacturer rebates under the Medicaid Drug Rebate Program. This shift provides more predictable reimbursement for providers but increases rebate exposure for manufacturers. The piece also explores the expansion of CAR-T administration into community outpatient settings and implications for access and reimbursement across payer types.

Avalere examines how state Medicaid programs are responding to budget pressure from the One Big Beautiful Bill Act, new provider tax restrictions, and rising utilization. States are adjusting managed care rates, benefits packages, and procurement timelines to navigate tighter fiscal conditions while managing administrative constraints. The analysis outlines decision-making factors that will shape state actions affecting MCO contracts and payment structures in the current budget cycle.

Gene therapies for rare diseases create structural tension between one-time treatments with multi-decade outcomes and payer systems built on annual budgets and short-term evidence cycles. With 26 FDA-approved gene therapies now in use and more coming, the piece argues healthcare delivery infrastructure and financing models—not just clinical science—will determine patient access and long-term sustainability. For Medicaid MCOs, this raises questions about payment structures, coverage decisions, and evidence generation obligations for high-cost, one-time interventions.

The U.S. Pharmacopeia's 2026 Drug Classification update revises how drugs are grouped for non-Part D health plan formularies, including Medicaid managed care plans. While primarily focused on Medicare Part D guidance, these classifications influence how all health plans structure formularies and could affect drug eligibility for upcoming Medicare international reference pricing demonstrations. The annual update cycle for non-Part D classifications offers Medicaid plans more frequent opportunities to engage on drug categorization than the three-year Medicare cycle.

The reconstituted Advisory Committee on Immunization Practices made changes to pediatric immunization schedules in December 2025 and signaled potential 2026 policy shifts affecting vaccines for HPV, RSV, influenza, and pregnancy-related immunizations. Because ACIP recommendations trigger mandatory Medicaid coverage without cost-sharing when published in official immunization schedules, these deliberations—and the committee's altered composition and process—carry direct implications for MCO benefit design, preventive care obligations, and pediatric and maternal health programs. The exclusion of traditional medical society liaisons from work groups may affect the clinical grounding of future recommendations that Medicaid plans must operationalize.

The 340B drug discount program reached $81.4 billion in 2024, with disproportionate share hospitals accounting for 78% of purchases. Many DSH hospitals also participate in Medicaid managed care, and pending federal reforms—including the 340B Rebate Model pilot and congressional bills—could reshape how these entities finance care for Medicaid beneficiaries. The program now exceeds Medicaid drug spending, making potential policy changes significant for state programs and MCOs contracting with 340B-eligible providers.

Major changes to the Advisory Committee on Immunization Practices—including replacement of all members and elimination of expert working groups—may affect Medicaid coverage requirements, since ACIP recommendations trigger mandatory coverage under federal law and determine which vaccines qualify for the Vaccines for Children program. The white paper examines how these structural changes could disrupt the evidence-based processes that underpin Medicaid immunization benefits and patient access protections.

Eight states have established Prescription Drug Affordability Review Boards (PDABs) to control drug costs, with four states (CO, MD, MN, WA) authorized to set Upper Price Limits that typically apply to both Medicaid and state-regulated commercial plans. Colorado became the first state to implement a UPL in October 2025, setting a $600 per-unit cap on Enbrel aligned with federal negotiated pricing. For Medicaid managed care plans operating in these states, PDABs represent a new layer of price regulation affecting pharmacy benefits and potentially reimbursement structures for approximately 7.8 million covered lives.

The Trump administration is encouraging manufacturers to launch direct-to-consumer drug purchasing platforms that bypass traditional pharmacy benefit structures, with 10 manufacturers now offering such programs. While these cash-pay and potentially insurance-integrated platforms promise price transparency and patient choice, they create uncertainty for Medicaid MCOs around claims tracking, formulary management, adherence monitoring, and Stars performance measurement. The piece explores manufacturer design considerations but does not substantively address Medicaid-specific implications.

A 50-state review finds persistent disparities in how Medicaid reimburses physician offices, pharmacies, and FQHCs for adult vaccines, with physician offices typically paid less than Medicare rates and pharmacies receiving low administration fees. While some states have modestly increased non-COVID vaccine administration rates and expanded pharmacy billing permissions, new federal fiscal constraints and potential ACIP recommendation changes may further pressure state vaccine access policies. These reimbursement structures directly affect managed care contracting strategies and network adequacy for preventive services.

Avalere outlines major federal health policy developments expected through the end of 2025, including Medicare Part D formulary changes, drug pricing negotiations, and ongoing PBM scrutiny under the Trump administration. While focused primarily on Medicare, the piece touches on broader regulatory trends around drug pricing and benefit management that affect Medicaid managed care operations and state policy planning. The analysis provides context for understanding how federal pharmaceutical policy changes may influence Medicaid managed care contracting and formulary strategies.

Federal legislation enacted in July 2025 introduces mandatory work requirements, accelerated eligibility redeterminations, and immigration status restrictions expected to affect 7.8 million Medicaid enrollees by 2034. The law also restricts states' use of provider taxes to finance their Medicaid programs, forcing significant changes to state funding strategies and managed care operations. MCOs will face new compliance obligations around work requirement verification, more frequent eligibility reviews, and dual market impacts as disenrolled members shift to exchange coverage.

Avalere examines how federal policy changes—including OBBBA Medicaid cuts, Medicare Part D redesign, and MFN pricing—are forcing pharmaceutical manufacturers to recalibrate market access strategies based on shifting payer mix across therapeutic areas. The analysis suggests Medicaid enrollment declines could push patients into commercial or uninsured coverage, affecting manufacturer uptake dynamics and requiring MCOs and state Medicaid programs to actively engage manufacturers to maintain therapeutic area prioritization. Manufacturers may need to redesign patient support programs and channel strategies as Medicaid's share of coverage for certain drugs contracts.

Avalere analyzes emerging state and federal legislation that would restrict or ban PBM ownership of pharmacies, following Arkansas's pioneering but contested prohibition. For Medicaid MCOs—which contract with PBMs for pharmacy benefits and must ensure adequate network access—these reforms could force restructuring of pharmacy relationships, potentially affecting network adequacy, pharmacy reimbursement models, and the vertical integration strategies that many health plans have pursued to control pharmacy costs.

Analysis of 2018-2022 Medicare Part D claims reveals growing pharmacy spending for beneficiaries in home and community-based settings, while nursing facility spending declined. This trend mirrors the broader shift in long-term services and supports delivery that Medicaid managed care organizations are navigating, particularly as states expand HCBS waivers and MCOs increasingly coordinate pharmacy benefits for dually eligible members receiving LTSS in non-institutional settings.